The American Cancer Society estimates that doctors will diagnose multiple myeloma in 34,470 people in the United States in 2022. Multiple myeloma, or myeloma, is a blood cancer that develops in plasma ...
Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and ...
Sarclisa, Velcade, Revlimid and dexamethasone improved progression-free survival in patients with multiple myeloma who were not eligible for transplant. A new drug combination called Isa-VRd was ...
January 27, 2026: The U.S. Food and Drug Administration (FDA) approved the quadruplet therapy daratamumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, lenalidomide, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results